JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma

Oncogene

Volumn 31, Issue 25, 2012, Pages 3098-3110

  Kanno, T ^a   Kamba, T ^a   Yamasaki, T ^a   Shibasaki, N ^a   Saito, R ^a   Terada, N ^a   Toda, Y ^a   Mikami, Y ^a   Inoue, T ^a   Kanematsu, A ^a   Nishiyama, H ^a   Ogawa, O ^a   Nakamura, E ^b  

^a KYOTO UNIVERSITY   (Japan)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

angiogenesis; JunB invasion; renal cell carcinoma; VHL gene

Indexed keywords

CXCL2 CHEMOKINE; GELATINASE A; GELATINASE B; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR JUNB; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; DENSITY; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MICROVASCULATURE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MICE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-JUN; TRANSPLANTATION, HETEROLOGOUS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84862694893     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.475     Document Type: Article

References (48)

1. Balkwill F. (2004). Cancer and the chemokine network. Nat Rev Cancer 4: 540-550.
2. Bian J, Sun Y. (1997). Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 17: 6330-6338.
3. Brugarolas J. (2007). Renal-cell carcinoma - molecular pathways and therapies. N Engl J Med 356: 185-187.
4. Calzada MJ. (2010). von Hippel-Lindau syndrome: molecular mechanisms of the disease. Clin Transl Oncol 12: 160-165.
5. Eferl R, Wagner EF. (2003). AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859-868.
6. Frew IJ, Krek W. (2008). pVHL: a multipurpose adaptor protein. Sci Signal 1: pe30.
7. Higgins JP, Shinghal R, Gill H, Reese JH, Terris M, Cohen RJ et al. (2003). Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 162: 925-932.
8. Kaelin Jr WG. (2008). The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873.
9. Kaelin Jr WG. (2009). Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 115: 2262-2272.
10. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. (2001). Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7: 3113-3119.
11. Keeley EC, Mehrad B, Strieter RM. (2008). Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol 28: 1928-1936.
12. Kondo K, Kim WY, Lechpammer M, Kaelin Jr WG. (2003). Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1: E83.
13. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin Jr WG. (2002). Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246.
14. Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM et al. (1999). The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 19: 5902-5912.
15. Kurban G, Duplan E, Ramlal N, Hudon V, Sado Y, Ninomiya Y et al. (2008). Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2. Oncogene 27: 1004-1012.
16. Kurban G, Hudon V, Duplan E, Ohh M, Pause A. (2006). Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res 66: 1313-1319.
17. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. (2005a). Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169: 681-691.
18. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP et al. (2005b). Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8: 155-167.
19. Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L et al. (2007). Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 13: 671s-679s.
20. Linehan WM, Zbar B. (2004). Focus on kidney cancer. Cancer Cell 6: 223-228.
21. Lu X, Kang Y. (2009). Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem 284: 29087-29096.
22. Martin T, Cardarelli PM, Parry GC, Felts KA, Cobb RR. (1997). Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-kappa B and AP-1. Eur J Immunol 27: 1091-1097.
23. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
24. Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, BrownM et al. (2010). Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 29: 2104-2117.
25. Nakamura E, Abreu-e-Lima P, Awakura Y, Inoue T, Kamoto T, Ogawa O et al. (2006). Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol 168: 574-584.
26. Nakamura E, Kaelin Jr WG. (2006). Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma. Endocr Pathol 17: 97-106.
27. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN et al. (1998). The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1: 959-968.
28. Ozanne BW, Spence HJ, McGarry LC, Hennigan RF. (2007). Transcription factors control invasion: AP-1 the first among equals. Oncogene 26: 1-10.
29. Passegue E, Jochum W, Behrens A, Ricci R, Wagner EF. (2002). JunB can substitute for Jun in mouse development and cell proliferation. Nat Genet 30: 158-166.
30. Perez-Gracia JL, Prior C, Guillen-Grima F, Segura V, Gonzalez A, Panizo A et al. (2009). Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer 101: 1876-1883.
31. Piechaczyk M, Farras R. (2008). Regulation and function of JunB in cell proliferation. Biochem Soc Trans 36: 864-867.
32. Rini BI, Atkins MB. (2009). Resistance to targeted therapy in renalcell carcinoma. Lancet Oncol 10: 992-1000.
33. Rini BI, Campbell SC, Escudier B. (2009). Renal cell carcinoma. Lancet 373: 1119-1132.
34. Roberts AM, Ohh M. (2008). Beyond the hypoxia-inducible factor-centric tumour suppressor model of von Hippel-Lindau. Curr Opin Oncol 20: 83-89.
35. Roy R, Yang J, Moses MA. (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27: 5287-5297.
36. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK et al. (2000). Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96: 34-40.
37. Schmidt D, Textor B, Pein OT, Licht AH, Andrecht S, Sator-Schmitt Met al. (2007). Critical role for NF-kappaB-induced JunB in VEGF regulation and tumor angiogenesis. EMBO J 26: 710-719.
38. Shaulian E. (2010). AP-1-the Jun proteins: oncogenes or tumor suppressors in disguise? Cell Signal 22: 894-899.
39. Song H, Ki SH, Kim SG, Moon A. (2006). Activating transcription factor 2 mediates matrix metalloproteinase-2 transcriptional activation induced by p38 in breast epithelial cells. Cancer Res 66: 10487-10496.
40. Staber PB, Vesely P, Haq N, Ott RG, Funato K, Bambach I et al. (2007). The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood 110: 3374-3383.
41. Struckmann K, Mertz K, Steu S, Storz M, Staller P, Krek W et al. (2008). pVHL coordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. J Pathol 214: 464-471.
42. Takahashi M, Oka N, Naroda T, Nishitani MA, Kanda K, Kanayama HO et al. (2002). Prognostic significance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma. Int J Urol 9: 531-538.
43. Terada N, Shimizu Y, Kamba T, Inoue T, Maeno A, Kobayashi T et al. (2010). Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res 70: 1606-1615.
44. Watanabe M, Sasaki M, Itoh K, Higashihara M, Umezawa K, Kadin ME et al. (2005). JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and Reed-Sternberg cells of Hodgkin lymphoma. Cancer Res 65: 7628-7634.
45. Weidner N. (1995). Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147: 9-19.
46. Woodward ER, Maher ER. (2006). von Hippel-Lindau disease and endocrine tumour susceptibility. Endocr Relat Cancer 13: 415-425.
47. Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, Zhang X et al. (2007). pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell 28: 15-27.
48. Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P et al. (2009). Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 15: 7582-7592.